Sterling Accuris Diagnostics Achieves 22% Growth in Fiscal Year 2025

Sterling Accuris Diagnostics marked a significant 22% year-on-year growth in its operational scale by the conclusion of the fiscal year ending March 2025. This Ahmedabad-based company notably reduced its losses and managed to achieve EBITDA positivity in the last fiscal year.

Revenue Growth Highlights

The organisation’s revenue from operations surged to Rs 198 crore in FY25, up from Rs 162 crore in FY24, as revealed by its consolidated financial statements sourced from the Registrar of Companies (RoC). Established in 2014, Sterling Accuris Diagnostics provides over 2,000 tests across approximately 150 laboratories and collection centres spread across four states. Testing services constitute its only revenue source.

Financial Performance Overview

In addition to its operational revenue, the firm generated Rs 4 crore from non-operational sources, leading to a total income of Rs 202 crore in FY25, an increase from Rs 169 crore in FY24. On the expenditure front, employee benefits emerged as the major cost at Rs 52 crore, reflecting an 18% rise from Rs 44 crore in FY24. Material expenses totalled Rs 45 crore, while fees for doctors and pathologists were at Rs 40 crore. Depreciation charges amounted to Rs 19 crore, alongside finance costs standing at Rs 6 crore in the fiscal year just ended.

Overall, Sterling Accuris Diagnostics’ total expenses climbed by 14%, reaching Rs 221 crore in FY25 compared to Rs 194 crore in FY24. For a detailed breakdown of expenses, consulting various sources may be beneficial.

Loss Mitigation and EBITDA Improvement

With revenue growth outstripping the increase in expenses, the firm successfully curtailed its losses by 15%, bringing them down to Rs 23 crore in FY25 from Rs 27 crore in FY24. Significantly, Sterling Accuris Diagnostics reported a positive EBITDA of Rs 5.5 crore in FY25, with the EBITDA margin enhancing to 2.72% from a previous -0.59%. The company’s Return on Capital Employed (ROCE) was recorded at -7.07%.

Unit Economics and Assets

On a unit basis, Sterling Accuris Diagnostics spent Rs 1.12 to generate a rupee in FY25, an improvement from Rs 1.20 in FY24. As of March 2025, the company had current assets valued at Rs 52 crore, which included Rs 22 crore in cash and bank balances.

Funding and Investor Details

According to various sources, Sterling Accuris has successfully amassed a total of $33 million in funding to date. Its prominent investors include Morgan Stanley, which holds a 35.64% stake, and Udhay Vi Realty, possessing a 17% share.